Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: An analysis based on in vivo observations

Drug Metabolism and Disposition

Volumn 42, Issue 9, 2014, Pages 1478-1484

  Abduljalil, Khaled ^a   Cain, Theresa ^a   Humphries, Helen ^a   Rostami Hodjegan, Amin ^a,b  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

BIOLOGICAL MODEL; HUMAN; IN VITRO STUDY; KINETICS; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; STATISTICS;

HUMANS; IN VITRO TECHNIQUES; KINETICS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; STATISTICS AS TOPIC;

EID: 84906848489     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058099     Document Type: Article

References (19)

1. Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, and Fuhr U (2010) Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 88:643-651.
2. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, and Novelli G (2007) Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8:1545-1550. (Pubitemid 350286398)
3. Castleden CM and George CF (1979) The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 7:49-54. (Pubitemid 9096745)
4. Chen Y, Jin JY, Mukadam S, Malhi V, and Kenny JR (2012) Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos 33:85-98.
5. Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 43:563-570. (Pubitemid 27283564)
6. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, and Eap CB (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593- 604.
7. Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, and Barter ZE (2011) Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:623-638.
8. Dorne JL, Walton K, and Renwick AG (2003) Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food Chem Toxicol 41:225-245. (Pubitemid 35447873)
9. Dorne JL, Walton K, Slob W, and Renwick AG (2002) Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem Toxicol 40:1633-1656.
10. Gibson CR, Bergman A, Lu P, Kesisoglou F, Denney WS, and Mulrooney E (2009) Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. Xenobiotica 39:637-648.
11. Gombar VK and Hall SD (2013) Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution. J Chem Inf Model 53:948-957.
12. Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, and Galetin A (2011) Critique of the twofold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos 39:170-173.
13. Han B, Mao J, Chien JY, and Hall SD (2013) Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos 41:1329-1338.
14. Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 36:473-497. (Pubitemid 43890728)
15. Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, and Rostami- Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. II: potential interethnic differences. Xenobiotica 36:499-513. (Pubitemid 43890729)
16. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, and Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
17. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, and Ezra D (2001) Interindividual variability in sensitivity to warfarin - Nature or nurture? Clin Pharmacol Ther 70:159-164.
18. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, and Latif A, et al. (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125:279-287.
19. Tucker GT (1994) Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 46 (Suppl 1):417-424.